User:Patriciagonzalezdias/sandbox

Daniela M. Ferreira
Born
Daniela M. Ferreira
CitizenshipBrazilian and British
EducationUniversity of São Paulo (SP)
University of São Paulo (PhD)
Known forResearch on Respiratory Infections and Covid-19 Vaccine trials
Scientific career
FieldsRespiratory tract infection, Vaccine and Immunology
InstitutionsLiverpool School of Tropical Medicine
Butantan institute
ThesisDNA vaccines against Streptococcus pneumoniae based on PspA (Pneumococcal surface protein A) and PspC (Pneumococcal surface protein C) (2009)
Academic advisorsStephen Gordon
Miyaji, Eliane Namie [1]

Daniela M. Ferreira is a Brazilian British immunologist. [2]She is a global leader in Human Infection Challenge with experience in bacterial challenge, respiratory co-infection, mucosal immunology and vaccine responses. She is currently the Head of Clinical Sciences Department and Professor of respiratory vaccines and infection immunology at Liverpool School of Tropical Medicine.[3] [4]She leads a team of scientists studying protective immune responses against pneumococcus [5] and other respiratory pathogens such as SARS-CoV2. Her team has established a novel method of inducing pneumococcal carriage in human volunteers. [5]. They use this model to:

  • Discover how people with risk factors (age, chronic lung disease) make responses to respiratory bacteria and virus and how this is different from healthy people
  • Pre-select vaccine candidates and test new vaccines more rapidly
  • Discover how the host alters the biology of the bacteria while it is being carried

Her team has played a substantial role in the UK covid-19 pandemic response as a trial site for several COVID-19 vaccine studies including the Oxford / Astrazeneca vaccine. [6][7][8]

Ferreira is part of the HIC-VACc onsortium [9] and Leads the WorkStream on Human Challenge Plataform to accelerate product development in the UKRI Infection Innovation Consortium (iicon)[10] .

Research and career

edit

Ferreira obtained a Degree and Bachelor's Degree in Biological Sciences in 2005 and a Ph.D. in Immunology in 2009, both from the University of São Paulo (São Paulo, Brazil). During her PhD, Ferreira was awarded the Robert Austrian Research Award in Pneumococcal Vaccinology. [11]

Ferreira joined the Respiratory Infection group at Liverpool School of Tropical Medicine as a postdoctoral fellow in December 2009 and together with Prof Stephen Gordon led the development of an Experimental Human Pneumococcal Nasopharyngeal Colonization Model. Ferreira was appointed Professor and subsequent Head of Department of Clinical Sciences in 2018. [3] In particular, her main lines of research are:

  • 1) Accelerate development and test novel pneumococcal vaccines using experimental carriage [5]
  • 2) Understanding nasal and lung immune responses and correlates of protection against respiratory infection with viruses including SARS-CoV2 and bacteria [5]
  • 3) Defining how respiratory virus co-infections (flu, RSV and SARS-CoV2) and host susceptibility (asthma, COPD, aging, smoke) alters responses to pneumococcal infection [5]

Key Publications

edit
  • Steenhuijsen Piters WAA, Jochems S, Mitsi E, Rylance J, Pojar S, Nikolaou E, German EL, Holloway M, Carniel BF, Chu MLJN, Arp K,. Sanders EAM, Ferreira DM* and Bogaert D.* Interaction between live-attenuated influenza vaccine, Streptococcus pneumoniae and the nasal microbiota. Nat Commun. 10, 2981 (2019), https://doi.org/10.1038/s41467-019-10814-9.[12]
  • Jochems SP, Marcon F, Carniel BF, Zaidi S, Piddock K, Wheeler I, Gordon SB, Rylance J, Nakaya H, Ferreira DM. Inflammation induced by influenza virus impairs innate control of human pneumococcal carriage. Nature Immunology. 2018 Dec;19(12):1299-1308. doi: 10.1038/s41590-018-0231-y. Epub 2018 Oct 29.[13]

References

edit
  1. ^ "Eliane Namie Miyaji". FAPESP. FAPESP. Retrieved 20 September 2021.
  2. ^ "Connecting immunology in the time of COVID-19". www.eventsforce.net. Retrieved 13 October 2021.
  3. ^ a b "Professor Daniela Ferreira". LSTM. Retrieved 13 October 2021.
  4. ^ "BBC Radio Merseyside with LSTM's Professor Daniela Ferreira". LSTM. Retrieved 13 October 2021.
  5. ^ a b c d e "Experimental Human Pneumococcal Carriage consortium". Liverpool School of Tropical Medicine. LSTM. Retrieved 15 September 2021.
  6. ^ "Oxford Covid vaccine 'safe and effective', Lancet study shows". LSTM. Retrieved 15 September 2021.
  7. ^ "UK vaccine volunteers to help prepare for next virus at new Pandemic Institute". the Guardian. 12 September 2021. Retrieved 13 October 2021.
  8. ^ "Brasileira que coordena testes com vacina para Covid-19 na Inglaterra explica dilema da prova de eficácia". G1 (in Brazilian Portuguese). Retrieved 13 October 2021.
  9. ^ "HIC-VACc onsortium". HIV-VAC. Retrieved 15 September 2021.
  10. ^ "iicon". LSTM. Retrieved 15 September 2021.
  11. ^ "Pneumococcus Human Infection Challenge and the Effect of Respiratory Virus Co-infections on Mucosal Immunity – Prof Daniela Ferreira". Imperial College London. Retrieved 13 October 2021.
  12. ^ Ferreira, Steenhuijsen; P. "Interaction between live-attenuated influenza vaccine, Streptococcus pneumoniae and the nasal microbiota". Nat Commun. doi:10.1172/JCI128865. PMID 31361601.
  13. ^ Ferreira, Jochems; SP. "Inflammation induced by influenza virus impairs innate control of human pneumococcal carriage". Nature Immunology. doi:10.1038/s41590-018-0231-y. PMID 30374129.



Category:Living people Category:Year of birth missing (living people) Category:Brazilian immunologists Category:Influenza researchers Category:Brazilian women scientists Category:Women immunologist Category:Academics of Liverpool School of Tropical Medicine Category:Alumni of the University of São Paulo